Nabla Bio
AI-driven design of therapeutic antibodies for complex diseases.
AI-driven design of therapeutic antibodies for complex diseases.
Nabla Bio, founded by AI and protein design experts from Harvard University, aims to revolutionize the pharmaceutical and biotech industries by enabling the development of more effective antibody therapies for intractable diseases. The company leverages artificial intelligence and massively parallel experimentation to design antibodies that precisely target disease sites while minimizing risks related to manufacturability and toxicity. Nabla Bio focuses on expanding the universe of druggable targets, using integrated AI and experimental technologies to achieve atomic precision in drug design.
Notable affiliated individuals include its founders, who are recognized experts in AI and protein design from Harvard University. Nabla Bio is a well-funded, revenue-generating company, indicating strong investor confidence and market traction. The company has made significant strides in the field of therapeutic antibody design, contributing to advancements in drug development for complex diseases. Its innovative approach has positioned Nabla Bio as a key player in the biotech industry, with a substantial impact on the future of precision medicine.
Companies similar to Nabla Bio include Macromoltek, BigHat Biosciences, Profluent Bio and Abterra Biosciences.
Nabla Bio was founded in 2020.
Nabla Bio's headquarters is located in Boston, MA, US.
Nabla Bio's most recent funding round was for $11M (USD) in December 2021.
As of Dec 6, 2021, Nabla Bio has disclosed funding of $11.4M (USD). Undisclosed round amounts are excluded.
Nabla Bio has 9 employees as of Feb 4, 2024.
Abterra Biosciences
abterrabio.com
